Particularly this HDAC3 involvement is of potential therapeutic interest, as subtype-specific HDAC inhibitors are currently being developed and could potentially be used to treat CREBBP-mutant lymphomas (110–113). This evidence concerns the gene CREBBP and lymphoma.